Back to Search
Start Over
Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the Eastern Cooperative Oncology Group.
- Source :
-
Cancer (0008543X) . Aug2007, Vol. 110 Issue 4, p759-763. 5p. 1 Chart, 2 Graphs. - Publication Year :
- 2007
-
Abstract
- <bold>Background: </bold>Paclitaxel and docetaxel are active agents in advanced urothelial cancer. BMS-247550 (ixabepilone) has activity in preclinical models in paclitaxel resistant models. A phase 2 trial of this epothilone was performed to determine the activity and toxicity of this agent in a multi-institutional setting in patients previously treated with 1 prior chemotherapy regimen.<bold>Methods: </bold>Forty-five patients with advanced urothelial carcinoma were treated with BMS-247550 40 mg/m(2) over 3 hours intravenously on Day 1 of a 21-day cycle and continued therapy until progression or unacceptable toxicity.<bold>Results: </bold>Five patients obtained an objective partial response (PR) among the 42 eligible patients for an overall response rate of 11.9% (90% confidence interval [5.3%, 26.5%]). Median overall survival of the group was 8 months. Toxicity was moderate with granulocytopenia, fatigue, and sensory neuropathy being the most common side effects noted.<bold>Conclusions: </bold>BMS-247550 (ixabepilone) has very modest activity as a second-line therapy for advanced urothelial cancer. Responses in visceral, nodal, and soft tissues sites were observed. Granulocytopenia without fever, fatigue, and sensory neuropathy was common. [ABSTRACT FROM AUTHOR]
- Subjects :
- *DRUG efficacy
*ANTINEOPLASTIC agents
*CLINICAL trials
*CANCER patients
*TUMORS
Subjects
Details
- Language :
- English
- ISSN :
- 0008543X
- Volume :
- 110
- Issue :
- 4
- Database :
- Academic Search Index
- Journal :
- Cancer (0008543X)
- Publication Type :
- Academic Journal
- Accession number :
- 27579961
- Full Text :
- https://doi.org/10.1002/cncr.22839